Jyothi Ranga Patri
Jyothi Ranga Patri has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Venkata Sushma Chamarthi
Department of Pediatrics, Valley Children’s Healthcare, Madera, CA 93636, USA
4 shared publications Mahika Shetty
Drexel University School of Medicine, Philadelphia, PA, USA
3 shared publications- Vignesh Gunasekaran
West Virginia University School of Medicine, West Virginia, United States
2 shared publications Pranavi Bandaru
University of Limerick School of Medicine, Limerick, Ireland
1 shared publicationShravan Gangula
Coffeyville Regional Medical Center, Coffeyville, KS, USA
1 shared publicationVenkata Sushma Chamarthi
Valley Children's Hospital, USA
1 shared publication
Latest Publications
- 22 June 2026
- Published by CABI Publishing in Food Science and Nutrition Cases
Ultra-Processed Foods and Pediatric Obesity: A Clinical Case for Evidence-Based Action in Primary Care
Ultra-processed foods (UPFs) are industrial formulations manufactured predominantly from refined ingredients and chemical additives. They are engineered to maximize palatability and shelf life. In the USA, UPFs now account for approximately 67% of total energy intake among children aged 2–19 years. This case study presents a composite de-identified clinical scenario of a 9-year-old boy presenting to primary care with obesity, elevated cardiometabolic markers, and a diet dominated by UPFs. The case draws on current evidence to examine the NOVA food classification system, socio-demographic drivers of UPF consumption, and health consequences spanning cardiometabolic, gut microbiome, neurodevelopmental, and oral health domains. Evidence-based screening tools and family-centered counseling approaches are discussed in the context of pediatric primary care. Policy responses at the school, community, and regulatory levels are also reviewed. This case study is intended for use in medical education, pediatric training, and continuing professional development across primary care, nutrition, dietetics, and public health. Information: © The Authors 2026
- 22 June 2026
- Published by CABI Publishing in Food Science and Nutrition Cases
Ultra-Processed Foods and Pediatric Obesity: A Clinical Case for Evidence-Based Action in Primary Care
Ultra-processed foods (UPFs) are industrial formulations manufactured predominantly from refined ingredients and chemical additives. They are engineered to maximize palatability and shelf life. In the USA, UPFs now account for approximately 67% of total energy intake among children aged 2–19 years. This case study presents a composite de-identified clinical scenario of a 9-year-old boy presenting to primary care with obesity, elevated cardiometabolic markers, and a diet dominated by UPFs. The case draws on current evidence to examine the NOVA food classification system, socio-demographic drivers of UPF consumption, and health consequences spanning cardiometabolic, gut microbiome, neurodevelopmental, and oral health domains. Evidence-based screening tools and family-centered counseling approaches are discussed in the context of pediatric primary care. Policy responses at the school, community, and regulatory levels are also reviewed. This case study is intended for use in medical education, pediatric training, and continuing professional development across primary care, nutrition, dietetics, and public health. Information: © The Authors 2026
- Open Access
- 1 June 2026
- Published by Elmer Press, Inc. in International Journal of Clinical Pediatrics
- Vol. 15 (2) , 37-50
Wearable Devices in Pediatric Obesity: A Comprehensive Review of Current Applications and Future Directions
Pediatric obesity represents a critical global public health crisis affecting millions of children and adolescents worldwide. Traditional obesity interventions face significant challenges related to adherence, engagement, and long-term efficacy. Wearable devices have emerged as promising tools for monitoring physical activity, metabolic parameters, and supporting behavior change in youth with obesity. This targeted literature review examines the current scope, applications, and effectiveness of wearable devices in managing childhood and adolescent obesity. We conducted a targeted literature review using PubMed and Google Scholar databases to identify studies published between 2010 and 2025. Search terms included wearable devices, pediatric obesity, activity trackers, accelerometers, continuous glucose monitors (CGMs), smartwatches, children, and adolescents. We focused on randomized controlled trials, systematic reviews, meta-analyses, and observational studies evaluating wearable devices in pediatric populations with obesity or overweight. Wearable devices demonstrate significant potential across multiple domains in pediatric obesity management. Activity trackers and accelerometers show effectiveness in increasing physical activity and improving anthropometric outcomes including body mass index (BMI), BMI z-score, and body fat percentage. Consumer-grade devices like Fitbit and research-grade accelerometers have shown acceptable accuracy and feasibility in pediatric populations. CGMs are emerging as valuable tools for understanding glycemic variability and supporting dietary behavior change in youth with obesity. Heart rate monitors and smartwatches provide real-time biofeedback that enhances engagement. However, heterogeneity in device types, intervention duration, and outcome measures limits definitive conclusions. In conclusion, wearable devices represent a versatile and increasingly accessible approach to pediatric obesity management. While current evidence supports their use for physical activity promotion and metabolic monitoring, significant gaps remain regarding long-term adherence, optimal implementation strategies, and integration into clinical care pathways. Future research should focus on standardizing outcome measures, evaluating cost-effectiveness, and developing age-appropriate interventions that maximize the unique potential of wearable technology in combating the pediatric obesity epidemic.
- 1 June 2026
- Published by Elmer Press, Inc. in International Journal of Clinical Pediatrics
- Vol. 15 (2) , 37-50
Open AccessWearable Devices in Pediatric Obesity: A Comprehensive Review of Current Applications and Future Directions
Pediatric obesity represents a critical global public health crisis affecting millions of children and adolescents worldwide. Traditional obesity interventions face significant challenges related to adherence, engagement, and long-term efficacy. Wearable devices have emerged as promising tools for monitoring physical activity, metabolic parameters, and supporting behavior change in youth with obesity. This targeted literature review examines the current scope, applications, and effectiveness of wearable devices in managing childhood and adolescent obesity. We conducted a targeted literature review using PubMed and Google Scholar databases to identify studies published between 2010 and 2025. Search terms included wearable devices, pediatric obesity, activity trackers, accelerometers, continuous glucose monitors (CGMs), smartwatches, children, and adolescents. We focused on randomized controlled trials, systematic reviews, meta-analyses, and observational studies evaluating wearable devices in pediatric populations with obesity or overweight. Wearable devices demonstrate significant potential across multiple domains in pediatric obesity management. Activity trackers and accelerometers show effectiveness in increasing physical activity and improving anthropometric outcomes including body mass index (BMI), BMI z-score, and body fat percentage. Consumer-grade devices like Fitbit and research-grade accelerometers have shown acceptable accuracy and feasibility in pediatric populations. CGMs are emerging as valuable tools for understanding glycemic variability and supporting dietary behavior change in youth with obesity. Heart rate monitors and smartwatches provide real-time biofeedback that enhances engagement. However, heterogeneity in device types, intervention duration, and outcome measures limits definitive conclusions. In conclusion, wearable devices represent a versatile and increasingly accessible approach to pediatric obesity management. While current evidence supports their use for physical activity promotion and metabolic monitoring, significant gaps remain regarding long-term adherence, optimal implementation strategies, and integration into clinical care pathways. Future research should focus on standardizing outcome measures, evaluating cost-effectiveness, and developing age-appropriate interventions that maximize the unique potential of wearable technology in combating the pediatric obesity epidemic.
- Open Access
- 1 April 2026
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 2, e18
Artificial Intelligence Applications in Pediatric Obesity Medicine: Bridging Predictive Analytics, Clinical Decision Support, and Family-Centered Care
Childhood obesity represents a significant public health challenge, affecting over 340 million children and adolescents worldwide. Despite the implementation of various intervention strategies, prevalence rates continue to rise. Artificial intelligence (AI) technologies offer considerable potential to address this crisis by enhancing risk prediction and individualizing treatment plans through scalable, family-oriented interventions. This review examines current evidence regarding AI applications in pediatric obesity medicine, with a focus on clinical utility, evaluation, and recommendations for future implementation. A comprehensive narrative review of the peer-reviewed literature was conducted to evaluate the applications of AI in pediatric obesity care. The review encompassed predictive analytics, clinical decision support systems (CDSS), remote monitoring technologies, and natural language processing (NLP) tools. PubMed, Scopus, and IEEE databases were systematically searched for studies published between 2015 and 2024 with a focus on validated AI systems with demonstrated clinical applications in pediatric populations. Studies were identified using combinations of keywords including “artificial intelligence,” “machine learning,” “deep learning,” “pediatric obesity,” “clinical decision support,” “predictive analysis,” “telemedicine,” “remote monitoring,” and “natural language processing.” Inclusion criteria included peer-reviewed English-language publications that described AI applications with relevance to pediatric obesity screening, prevention, or management. Studies were excluded if they addressed adult populations exclusively or focused on AI methodology without clinical application. Reference lists of relevant articles were also reviewed to identify additional eligible studies. Two authors (JRP and VSC) independently screened titles and abstracts, with discrepancies resolved through discussion. It is important to note that no AI system is currently approved or used in routine pediatric obesity clinical care; most applications described in this review remain in research or early pilot phases. AI applications demonstrate significant potential in managing various aspects of pediatric obesity. Machine learning algorithms facilitate earlier identification of high-risk children, achieving 75–90% accuracy in predicting obesity risk, as reported in studies employing logistic regression, random forest, and gradient boosting models on longitudinal electronic health record datasets. CDSS can generate effective treatment recommendations tailored to individual metabolic profiles, behavioral patterns, and family circumstances. Remote monitoring platforms that incorporate wearable devices and mobile health applications enable patient engagement and real-time adjustments to interventions. Automated screening and documentation through NLP tools may reduce clinician workload and enhance care quality. However, major implementation challenges include algorithmic bias, data breach risks, limited interoperability, and disparities in patient access to technology. AI applications enhance prediction accuracy, enable personalized interventions, and increase scalability, thereby offering substantial opportunities to advance pediatric obesity care. Key steps for effective integration involve addressing technical challenges, enhancing equity and access, ensuring clinical oversight, and adhering to family-centered care principles. Future research should prioritize improving validation across diverse populations by assessing long-term outcomes and developing implementation frameworks that support, rather than replace, the therapeutic relationship between communities and healthcare providers.
- 1 April 2026
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 2, e18
Open AccessArtificial Intelligence Applications in Pediatric Obesity Medicine: Bridging Predictive Analytics, Clinical Decision Support, and Family-Centered Care
Childhood obesity represents a significant public health challenge, affecting over 340 million children and adolescents worldwide. Despite the implementation of various intervention strategies, prevalence rates continue to rise. Artificial intelligence (AI) technologies offer considerable potential to address this crisis by enhancing risk prediction and individualizing treatment plans through scalable, family-oriented interventions. This review examines current evidence regarding AI applications in pediatric obesity medicine, with a focus on clinical utility, evaluation, and recommendations for future implementation. A comprehensive narrative review of the peer-reviewed literature was conducted to evaluate the applications of AI in pediatric obesity care. The review encompassed predictive analytics, clinical decision support systems (CDSS), remote monitoring technologies, and natural language processing (NLP) tools. PubMed, Scopus, and IEEE databases were systematically searched for studies published between 2015 and 2024 with a focus on validated AI systems with demonstrated clinical applications in pediatric populations. Studies were identified using combinations of keywords including “artificial intelligence,” “machine learning,” “deep learning,” “pediatric obesity,” “clinical decision support,” “predictive analysis,” “telemedicine,” “remote monitoring,” and “natural language processing.” Inclusion criteria included peer-reviewed English-language publications that described AI applications with relevance to pediatric obesity screening, prevention, or management. Studies were excluded if they addressed adult populations exclusively or focused on AI methodology without clinical application. Reference lists of relevant articles were also reviewed to identify additional eligible studies. Two authors (JRP and VSC) independently screened titles and abstracts, with discrepancies resolved through discussion. It is important to note that no AI system is currently approved or used in routine pediatric obesity clinical care; most applications described in this review remain in research or early pilot phases. AI applications demonstrate significant potential in managing various aspects of pediatric obesity. Machine learning algorithms facilitate earlier identification of high-risk children, achieving 75–90% accuracy in predicting obesity risk, as reported in studies employing logistic regression, random forest, and gradient boosting models on longitudinal electronic health record datasets. CDSS can generate effective treatment recommendations tailored to individual metabolic profiles, behavioral patterns, and family circumstances. Remote monitoring platforms that incorporate wearable devices and mobile health applications enable patient engagement and real-time adjustments to interventions. Automated screening and documentation through NLP tools may reduce clinician workload and enhance care quality. However, major implementation challenges include algorithmic bias, data breach risks, limited interoperability, and disparities in patient access to technology. AI applications enhance prediction accuracy, enable personalized interventions, and increase scalability, thereby offering substantial opportunities to advance pediatric obesity care. Key steps for effective integration involve addressing technical challenges, enhancing equity and access, ensuring clinical oversight, and adhering to family-centered care principles. Future research should prioritize improving validation across diverse populations by assessing long-term outcomes and developing implementation frameworks that support, rather than replace, the therapeutic relationship between communities and healthcare providers.
- Open Access
- 21 February 2026
- Published by Medip Academy in International Journal of Contemporary Pediatrics
- Vol. 13 (3) , 505-511
Brucellosis presenting as prolonged fever of unknown origin in a two-year-old child: a diagnostic challenge
Brucellosis is a zoonotic disease with diverse clinical manifestations and is an uncommon but important cause of prolonged fever in children. Diagnosis may be delayed due to nonspecific symptoms, limited exposure history, and variable serologic findings. This report describes a two-year-old patient who experienced 17 days of recurrent fever associated with fatigue, myalgia, and diarrhea following a horse-related injury two months earlier. Extensive evaluation demonstrated elevated inflammatory markers, thrombocytosis, cervical lymphadenopathy, and hepatic lesions, but the etiology was unrevealing. A thorough exposure history prompted targeted zoonotic testing, which identified Brucella-positive IgM in the absence of detectable IgG, consistent with an acute Brucella infection in the appropriate clinical context. This case highlights the importance of detailed exposure history and consideration of brucellosis in the differential diagnosis of pediatric fever of unknown origin (FUO), even in the absence of classic presentation.
- 21 February 2026
- Published by Medip Academy in International Journal of Contemporary Pediatrics
- Vol. 13 (3) , 505-511
Open AccessBrucellosis presenting as prolonged fever of unknown origin in a two-year-old child: a diagnostic challenge
Brucellosis is a zoonotic disease with diverse clinical manifestations and is an uncommon but important cause of prolonged fever in children. Diagnosis may be delayed due to nonspecific symptoms, limited exposure history, and variable serologic findings. This report describes a two-year-old patient who experienced 17 days of recurrent fever associated with fatigue, myalgia, and diarrhea following a horse-related injury two months earlier. Extensive evaluation demonstrated elevated inflammatory markers, thrombocytosis, cervical lymphadenopathy, and hepatic lesions, but the etiology was unrevealing. A thorough exposure history prompted targeted zoonotic testing, which identified Brucella-positive IgM in the absence of detectable IgG, consistent with an acute Brucella infection in the appropriate clinical context. This case highlights the importance of detailed exposure history and consideration of brucellosis in the differential diagnosis of pediatric fever of unknown origin (FUO), even in the absence of classic presentation.
- Open Access
- 5 January 2026
- Published by European Open Science in European Journal of Medical and Health Sciences
- Vol. 8 (1) , 72-76
Antiphospholipid Antibody Syndrome in Systemic Lupus Erythematosus: A Rare Case Report
Antiphospholipid Syndrome (APS) is an autoimmune disorder characterized by abnormal immune responses that disrupt blood coagulation and adversely impact pregnancy outcomes. In patients with systemic lupus erythematosus (SLE), APS often results in more complex clinical presentations and heightened management challenges. Diagnosis is frequently complicated by overlapping clinical features with other disorders and by laboratory findings that may be unclear, leading to delayed recognition. This report describes a 31-year-old woman with known SLE who presented with acute left upper-extremity swelling and was found to have venous thromboses in multiple armveins. Her history of recurrent pregnancy loss and Raynaud’s phenomenon raised suspicion of autoimmune etiology. Antibody testing demonstrated persistent positivity for lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I (aβ2GP1) antibodies, confirming the diagnosis of APS. The patient was initially treated with Lovenox and subsequently switched to warfarin for long-term management because of her high-risk profile. This case highlights that APS can present with atypical manifestations and underscores the importance of early evaluation and repeat testing in patients who develop thrombosis without typical risk factors.
- 5 January 2026
- Published by European Open Science in European Journal of Medical and Health Sciences
- Vol. 8 (1) , 72-76
Open AccessAntiphospholipid Antibody Syndrome in Systemic Lupus Erythematosus: A Rare Case Report
Antiphospholipid Syndrome (APS) is an autoimmune disorder characterized by abnormal immune responses that disrupt blood coagulation and adversely impact pregnancy outcomes. In patients with systemic lupus erythematosus (SLE), APS often results in more complex clinical presentations and heightened management challenges. Diagnosis is frequently complicated by overlapping clinical features with other disorders and by laboratory findings that may be unclear, leading to delayed recognition. This report describes a 31-year-old woman with known SLE who presented with acute left upper-extremity swelling and was found to have venous thromboses in multiple armveins. Her history of recurrent pregnancy loss and Raynaud’s phenomenon raised suspicion of autoimmune etiology. Antibody testing demonstrated persistent positivity for lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I (aβ2GP1) antibodies, confirming the diagnosis of APS. The patient was initially treated with Lovenox and subsequently switched to warfarin for long-term management because of her high-risk profile. This case highlights that APS can present with atypical manifestations and underscores the importance of early evaluation and repeat testing in patients who develop thrombosis without typical risk factors.